These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 17269931)
1. Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism. Vandel P; Talon JM; Haffen E; Sechter D Curr Pharm Des; 2007; 13(2):241-50. PubMed ID: 17269931 [TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics in psychiatry--a useful clinical tool or wishful thinking for the future? Kirchheiner J; Seeringer A; Viviani R Curr Pharm Des; 2010; 16(2):136-44. PubMed ID: 20205659 [TBL] [Abstract][Full Text] [Related]
3. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. de Leon J; Armstrong SC; Cozza KL Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Llerena A; Dorado P; Peñas-Lledó EM Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711 [TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. Kirchheiner J; Rodriguez-Antona C CNS Drugs; 2009; 23(3):181-91. PubMed ID: 19320528 [TBL] [Abstract][Full Text] [Related]
7. Personalized medicine in psychiatry: new technologies and approaches. Costa e Silva JA Metabolism; 2013 Jan; 62 Suppl 1():S40-4. PubMed ID: 23018148 [TBL] [Abstract][Full Text] [Related]
8. Clinical applications of pharmacogenetics in psychiatry. Staddon S; Arranz MJ; Mancama D; Mata I; Kerwin RW Psychopharmacology (Berl); 2002 Jun; 162(1):18-23. PubMed ID: 12107612 [TBL] [Abstract][Full Text] [Related]
9. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Bousman C; Maruf AA; Müller DJ Curr Opin Psychiatry; 2019 Jan; 32(1):7-15. PubMed ID: 30299306 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. de Leon J; Arranz MJ; Ruaño G Clin Lab Med; 2008 Dec; 28(4):599-617. PubMed ID: 19059065 [TBL] [Abstract][Full Text] [Related]
11. Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs. Dorado P; Berecz R; Peñas-Lledó EM; Cáceres MC; Llerena A Curr Drug Targets; 2006 Dec; 7(12):1671-80. PubMed ID: 17168842 [TBL] [Abstract][Full Text] [Related]
12. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. de Leon J Expert Rev Mol Diagn; 2006 May; 6(3):277-86. PubMed ID: 16706732 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacogenetics/pharmacogenomics in psychiatry]. Ueda M; Ishiguro S; Watanabe T; Saeki Y; Shimoda K Nihon Rinsho; 2010 Jan; 68(1):155-62. PubMed ID: 20077810 [TBL] [Abstract][Full Text] [Related]
14. Implementation of CYP2D6 genotyping in psychiatry. Loovers HM; van der Weide J Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1065-77. PubMed ID: 19572825 [TBL] [Abstract][Full Text] [Related]
15. Have we successfully implemented CYP2D6 genotyping in psychiatry? de Leon J Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1201-1203. PubMed ID: 29164956 [No Abstract] [Full Text] [Related]
16. Clinical Application of Therapeutic Drug Monitoring and Pharmacogenetics in Psychiatry, with a Focus on Belgium. Casterman A; de Timary P Psychiatr Danub; 2024 Sep; 36(Suppl 2):338-341. PubMed ID: 39378493 [TBL] [Abstract][Full Text] [Related]
18. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Bousman CA; Jaksa P; Pantelis C Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243 [TBL] [Abstract][Full Text] [Related]
19. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Stingl JC; Brockmöller J; Viviani R Mol Psychiatry; 2013 Mar; 18(3):273-87. PubMed ID: 22565785 [TBL] [Abstract][Full Text] [Related]
20. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. De Gregori M; Allegri M; De Gregori S; Garbin G; Tinelli C; Regazzi M; Govoni S; Ranzani GN Curr Drug Metab; 2010 Mar; 11(3):276-82. PubMed ID: 21171195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]